Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284797 | 0.93 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL16561569 | 0.92 | TSHR (0.47) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL16561496 | 0.90 | ALDH1A1 (0.45) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL6355801 | 0.87 | ALDH1A1 (0.52) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL8766941 | 0.85 | THRB (0.58) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL21985904 | 0.85 | MEN1 (0.44) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL1799910 | 0.83 | TSHR (0.44) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL284885 | 0.83 | TSHR (0.50) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL2895300 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL12607040 | 0.82 | TSHR (0.61) | TSHRALDH1A1TP53HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109037770-B | Preparation method of all-solid-state polymer electrolyte | 珠海冠宇电池股份有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-109037769-B | Preparation method of gel polymer electrolyte with composite carbonic acid cross-linked structure | 珠海冠宇电池股份有限公司 | 2021-09-07 | — | — | CN | claimed |
| US-10668676-B2 | Ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2020-06-02 | — | — | US | claimed |
| US-20200047437-A1 | OPHTHALMIC DEVICES | MEDICIS PHARMACEUTICAL CORPORATION | 2020-02-13 | — | — | US | claimed |
| EP-3091050-B1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES GMBH (CH) | 2018-07-18 | — | — | EP | claimed |
| US-9814801-B2 | Thiol-ene polymerization with vinylesters and vinylcarbonate | DePuy Synthes Products, Inc. (US) | 2017-11-14 | — | — | US | claimed |
| EP-3091050-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | Synthes GmbH (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20160243279-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES GMBH (CH) | 2016-08-25 | — | — | US | claimed |
| EP-2764049-B1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES GMBH (CH) | 2016-08-17 | — | — | EP | claimed |
| EP-2764049-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | Synthes GmbH (CH) | 2014-08-13 | — | — | EP | claimed |
| WO-2013052328-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES USA, LLC (US) | 2013-04-11 | — | — | WO | claimed |
| US-20130084543-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | TECHNISCHE UNIVERSITAT WIEN (AT) | 2013-04-04 | — | — | US | claimed |
| EP-4396616-A1 | OPHTHALMIC DEVICES | Bausch + Lomb Ireland Limited (IE) | 2024-07-10 | — | — | EP | disclosed |
| US-11897985-B2 | Water extractable ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2024-02-13 | — | — | US | disclosed |
| US-11873361-B2 | Ophthalmic devices | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-01-16 | — | — | US | disclosed |
| US-20230089707-A1 | OPHTHALMIC DEVICES | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2023-03-23 | — | — | US | disclosed |
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITAT WIEN (AT) | 2010-12-02 | — | — | US | disclosed |
| EP-2219697-A2 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | Technische Universität Wien (AT) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065162-A2 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065162-A2 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084543-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | TMT1A, MGMT, CBS | TSHR 2137/4885ALDH1A1 335/4885TP53 2278/4885 |
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | SCO2, CBR1, CBR3 | TSHR 4555/4885ALDH1A1 822/4885TP53 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.